Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.

Abstract excerpt

Spinal muscular atrophy (SMA) is the most common genetic cause of infantile death caused by mutations in the SMN1 gene. Nusinersen (Spinraza), an antisense therapy-based drug with the 2'-methoxyethoxy (2'MOE) chemistry approved by the FDA in 2016, brought antisense drugs into the spotlight. Antisense-mediated exon inclusion targeting SMN2 leads to SMN protein expression. Although effective, 2'MOE has weaknesses...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Exons
• Share to Gene Expression Regulation
• Share to Mice, Knockout